Effect of masupirdine (SUVN‐502) on cognition in patients with moderate Alzheimer's disease: A randomized, double‐blind, phase 2, proof‐of‐concept study

Effect of masupirdine (SUVN‐502) on cognition in patients with moderate Alzheimer's disease: A randomized, double‐blind, phase 2, proof‐of‐concept study

Abstract Introduction This study explored the efficacy and safety of a serotonin‐6 receptor antagonist, masupirdine, as adjunct treatment in patients with moderate Alzheimer's disease (AD) concomitantly treated with donepezil and memantine. Methods The effects of masupirdine were evaluated in p...

Full description

Bibliographic Details
Main Authors: Ramakrishna Nirogi, John Ieni, Vinod Kumar Goyal, Jyothsna Ravula, Satish Jetta, Anil Shinde, Pradeep Jayarajan, Vijay Benade, Veera Raghava Chowdary Palacharla, Dhanunjay Kumar Dogiparti, Venkat Jasti, Alireza Atri, Jeffrey Cummings
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
5‐HT6 receptor
Alzheimer's Disease Assessment Scale–Cognitive subscale
Alzheimer's disease
Clinical Dementia Rating–Sum of Boxes
clinical trials
masupirdine
Online Access:https://doi.org/10.1002/trc2.12307

Internet

https://doi.org/10.1002/trc2.12307

Similar Items